Observational studyJournal of immunology research2021
Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response.
Observational study in Journal of immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 40 citations in OpenAlex.
- Gut microbiome remodeling across hepatocellular carcinoma progression and transarterial chemoembolization is associated with therapeutic response and prognosis.Clinical and experimental medicine · 2026Article
- Gut microbiota-metabolism-immunity axis: a novel perspective of traditional Chinese medicine in hepatocellular carcinoma treatment.Chinese medicine · 2026Article
- Interactions Between Perioperative Anesthesia Management and Gut Microbiota: Current Research Advances.Cellular and molecular neurobiology · 2026Review
- Review
- Gut microbial signatures of advanced hepatocellular carcinoma and their potential diagnostic value.Frontiers in microbiology · 2026Article
- Gut Feelings: How Microbes, Diet, and Host Immunity Shape Disease.Biomedicines · 2025Review
- Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota.Cell death discovery · 2025Review
- Chemokines: Orchestration of the Tumor Microenvironment and Control of Hepatocellular Carcinoma Progression.Cancer medicine · 2025Review
- Gut microbiome and liver diseases.Fundamental research · 2025Review
- The Role of I-FABP, REG3α, sCD14-ST, and LBP as Indicators of GI Tract Injury in MODS Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Gut Microbiota and the Gut-liver Axis in Hepatocellular Carcinoma: A Comprehensive Review of Pathogenesis and Therapeutic Strategies.Anti-cancer agents in medicinal chemistry · 2025Review
- Shotgun Metagenomics RevealsGastro hep advances · 2025Review
- HIV-associated gut dysbiosis drives oncogenesis through metabolic-immune crosstalk: mechanisms and therapeutic implications.Frontiers in oncology · 2025Review
- Decoding the microbial-local immune dialogue in liver cancer: from ecological drivers to precision therapeutics.Frontiers in oncology · 2025Review
- Analyzing the gut liver axis: a dual role of the microbiome in the genesis, progression, and treatment of liver cell carcinoma.Frontiers in microbiology · 2025Review
- Gut microbiota-immunity cascade in hepatocellular carcinoma: mechanisms and therapeutic opportunities.Oncology reviews · 2025Review
- Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma.Biomedicines · 2024Review
- Protection from environmental enteric dysfunction and growth improvement in malnourished newborns by amplification of secretory IgA.Cell reports. Medicine · 2024Article
- Association between gut microbiota and hepatocellular carcinoma and biliary tract cancer: A mendelian randomization study.World journal of clinical cases · 2024Article
- Notch Signaling Inhibition Alleviates Allergies Caused by Antarctic Krill Tropomyosin through Improving Th1/Th2 Imbalance and Modulating Gut Microbiota.Foods (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
methodThis study included 74 Chinese male patients with HCC. They were divided into early (
resultsIn early, intermediate, and terminal groups, the abundance of the
conclusionGut microbiota compositional and functional shift, together with elevated gut damage and microbial translocation, may promote HCC development by stimulating inflammatory response and suppressing T cell response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.